NEW YORK, June 24 2014 / PRNewswire /– Reportlinker.com announces that a brand-new marketing research report is readily available in its brochure:

AVP-825 (Migraine) – Forecast and Market Analysis to 2023


AVP-825 (Migraine) – Projection and Market Analysis to 2023


The migraine market is saturated with generic medications, and the remaining branded products already on the market are expected to shed exclusivity throughout the next few years, with the exemption of Botox for persistent migraine, which is anticipated to maintain its leading position in regards to sales. However, reformulations of fully grown products as well as new courses of treatments are expected to introduce throughout the projection period and these will certainly add to the market growth. By 2023, the migraine market will certainly grow to $3.7 billion at a compound yearly growth fee (CAGR) of 3.6 %, with the United States continuouslying control the market as an outcome of greater drug rates and a large migraine populace. Several of the brand-new procedures are anticipated to target the vital unmet requirements but chances will continue to be for additional procedure options particularly medications that will supply an improved safety and security and side-effects profile.

OptiNose, a personal health care gadget company, is creating a low-dose sumatriptan powder formula to be supplied intranasally using its breath-powered nasal delivery modern technology. The innovation has actually been created to deliver drugs effectively and accurately to the targeted, hard-to-reach locations. Avanir will certainly hold obligations for governing, production, supply-chain and commercialization tasks for AVP-825.


– Review of Migraine, consisting of public health, etiology, symptoms, medical diagnosis, pathology and therapy guidelines and also a summary on the affordable landscape.
– Outlined information on AVP-825 including product description, security and effectiveness profiles and also a SWOT analysis.
– Sales forecast for AVP-825 for the United States from 2012 to 2023.
– Sales information covered for the United States.

Reasons to buy

– Understand and utilize by determining items that are most likely to guarantee a durable return
– Stay in advance of the competition by comprehending the altering affordable landscape for Migraine
– Efficiently prepare your M&A and partnership strategies by recognizing medications with one of the most encouraging sales potential
– Make more knowledgeable business decisions from insightful and thorough evaluation of AVP-825 performance
– Obtain sales projection for AVP-825 from 2012-2023 in the United States.
1 Tabulation

2 Intro 9
2.1 Stimulant 9
2.2 Associated Reports 9
2.3 Upcoming Related Information 11
3 Disease Summary 12
3.1 Etiology and Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 15
3.1.3 Outlook 16
3.2 Manifestations 16
3.2.1 Premonitory Stage 16
3.2.2 Feeling Stage 17
3.2.3 Headache Phase 17
3.2.4 Postdrome Stage 18
4 Condition Management 19
4.1 Therapy Summary 19
4.1.1 Acute Migraine Treatment 22
4.1.2 Preventive Migraine Procedure 23
5 Competitive Analysis 24
5.1 Overview 24
5.2 Strategic Rival Assessment 25
6 Possibility and Unmet Requirement 26
6.1 Summary 26
6.1.1 A Lack of Acute Therapies for Patients with or at Risk of Cardiovascular Disorders 27
6.1.2 Lack of Acute Therapies for Clients Unresponsive to Triptan Medicine 27
6.1.3 Lack of Diagnostic Tools Causes Misdiagnosis 28
6.1.4 Medical professional Education and learning 28
6.1.5 Effective and Well-Tolerated Prophylactic Therapies 29
6.2 Unmet Demands Space Evaluation 29
6.2.1 Acute Therapies for People with or in danger of Cardiovascular Disorders and for Patients Unresponsive to Triptan Medication 30

6.2.2 Effective and Well-Tolerated (Migraine-Specific) Preventive Therapies 31
6.2.3 Doctor Education 31
6.2.4 Diagnostic Tools 32
7 Pipe Analysis 33
7.1 Overview 33
7.2 Guaranteeing medications in professional advancement 34
8 AVP-825 37
8.1 Overview 37
8.2 Efficacy 38
8.3 Safety and security 39
8.4 Dosing and Formulation 39
8.5 Possible Medical Positioning 40
8.6 Possible Commercial Positioning 41
8.7 Prices and Compensation 41
8.8 SWOT Evaluation 42
8.9 Forecast 43
9 Appendix 44
9.1 Bibliography 44
9.2 Abbreviations 47
9.3 Methodology 48
9.4 Projecting Approach 48
9.4.1 Diagnosed Migraine Patients 49
9.4.2 Percent Drug-treated Clients 49
9.4.3 General Pricing Assumptions 49
9.4.4 Generic Erosion 50
9.4.5 Pricing of Pipe agents 50
9.5 Physicians and Specialists Included in this Research study 51
9.6 Survey of Prescribing Physicians 52
9.7 About the Authors 53
9.7.1 Author 53
9.7.2 Reviewer 53
9.7.3 International Head of Health care 53
9.8 Concerning GlobalData 55
9.9 Please note 55

1.1 Listing of Tables

Table 1: Classification of Migraine Subtypes 13
Table 2: Diagnostic Standard for Migraine with Feeling 17
Table 3: Diagnostic Standard for Migraine without Mood 18
Table 4: Therapy Tips for Migraine 20
Table 5: Most Prescribed Medications for Migraine by Class in the Major Markets, 2013 21
Table 6: General Unmet Needs – Present Degree of Attainment 26
Table 7: Scientific Unmet Requirements – Gap Evaluation, 2013 30
Table 8: Migraine – Vowing Late-Stage Pipeline, 2013 34
Table 9: Comparison of Therapeutic Lessons in Development for Migraine, 2013 36
Table 10: Item Profile – AVP-825 38
Table 11: AVP-825 SWOT Evaluation, 2013 42
Table 12: International Sales Forecasts ($m) for AVP-825, 2012-2023 43
Table 13: Physicians Surveyed, By Nation 52

1.2 Listing of Amounts

Figure 1: Migraine Treatment Formula in the 7MM 21
Amount 2: Affordable Analysis of Late-Stage Pipeline Brokers in Migraine, 2012-2023 35

To buy this report: AVP-825 (Migraine) – Forecast and Market Evaluation to 2023

Get in touch with Clare: [email protected]
United States: (339)-368 -6001
Intl: +1 339-368-6001


    Download your FREE Report on Headache


    Just a sneak peek…

    • Guide to cluster headache
    • Why do you get a headache?
    • Headache and migraine pain relief through hypnotherapy
    • Can stress cause severe headache?
    • Caffeine: the culprit behind our migraines
    • Menopause and headaches
    • Sinusitis: how serious is it?
    Download It Completely FREE

    Just Insert Your Name and email

    We will also send you a Complimentary copy of our Headache Newsletter. Our newsletter subscription has the latest information on Headache and Migraine treatments.

    We respect your privacy. We will NEVER sell, rent or share your email address. That’s more than a policy, it’s our personal guarantee!

  • Now you can have the Latest News on Headache


    Worried about Headache and Migraine? You can have now information about the latest treatments and medical research. All this and more in our Headache Newsletter.slide11t

    Try it for four weeks. We will even send you FREE our bonus health e-book with your trial subscription.

    All for just ONE PENNY

    Get the latest information – don’t be left in the dark on your condition.


    Check our special offer: Subscribe to one newsletter, get another newsletter for FREE!